Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash from Operations (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Cash from Operations for 6 consecutive years, with 1866179.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 82.9% to 1866179.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 7044549.0, a 17.52% increase, with the full-year FY2024 number at 7502700.0, up 30.4% from a year prior.
  • Cash from Operations was 1866179.0 for Q3 2025 at Ensysce Biosciences, up from 2706868.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 132312.0 in Q2 2021 to a low of 6714311.0 in Q3 2022.
  • A 5-year average of 2668039.84 and a median of 2706868.0 in 2025 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 3256.08% in 2022, then soared 66.3% in 2023.
  • Ensysce Biosciences' Cash from Operations stood at 3767813.0 in 2021, then grew by 12.53% to 3295620.0 in 2022, then surged by 45.33% to 1801875.0 in 2023, then soared by 57.59% to 764090.0 in 2024, then tumbled by 144.24% to 1866179.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Cash from Operations are 1866179.0 (Q3 2025), 2706868.0 (Q2 2025), and 1707412.0 (Q1 2025).